

Internship Report

Submitted



The IIHMR University, Jaipur

for the partial fulfilment for the award of the degree of
Master of Business Administration (MBA)
in
Pharmaceutical Management

By

Akshay Narayan Shinde

2024

Internship Report

Name: Akshay Narayan Shinde

Roll No:0367

Organization: Mankind Pharmaceutical. Ltd

Submitted To: Mr. Saurabh Kumar Banerjee

Title: “Strategic Management Framework for OSD Generic Drug Development in US and EU Markets”

1. Introduction

1.1 Project Overview This internship report outlines my work on the project titled "Strategic Management Framework for OSD Generic Drug Development in US and EU Markets: A Comprehensive Analysis and Implementation Strategy." The project focuses on the development and regulatory filing processes for oral solid dosage (OSD) generic drugs in both the US and EU markets, covering key phases from pre-formulation to regulatory submission.

1.2 Objectives

- To provide a detailed timeline and budgeting plan for OSD generic drug development.
- To identify and analyze potential risks and suggest mitigation strategies.
- To recommend tools and techniques for successful drug development and regulatory approval.

2. Phases of Drug Development

2.1 Pre-Formulation and Process Investigation (PPIF)

- Activities: Compound characterization, solubility studies, and initial stability testing.
- Timeline: 3-6 months.
- Budget: \$100,000 - \$200,000.
- Risks: Compound instability, inaccurate characterization.
- Mitigation: Robust initial testing, use of advanced characterization tools.

2.2 New Product Development (NPD)

- Activities: Prototype development, selection of excipients, formulation studies.
- Timeline: 6-12 months.
- Budget: \$200,000 - \$400,000.
- Risks: Prototype failure, unsuitable excipients.
- Mitigation: Extensive prototype testing, thorough excipient compatibility studies.

2.3 Formulation and Analytical Development

- Activities: Finalizing formulation, developing analytical methods.
- Timeline: 6-12 months.
- Budget: \$150,000 - \$300,000.
- Risks: Formulation instability, analytical method failure.

- Mitigation: Rigorous formulation testing, validation of analytical methods.

2.4 Pilot Studies

- Activities: Small-scale production, initial clinical testing.
- Timeline: 6-9 months.
- Budget: \$250,000 - \$500,000.
- Risks: Pilot batch failure, clinical adverse reactions.
- Mitigation: Detailed pilot study design, close monitoring of clinical outcomes.

2.5 Analytical Method Validation and Transfer (AMV/AMT)

- Activities: Validation of analytical methods, transfer to production sites.
- Timeline: 3-6 months.
- Budget: \$100,000 - \$200,000.
- Risks: Method validation failure, transfer issues.
- Mitigation: Comprehensive validation protocols, thorough transfer procedures.

2.6 Scale-Up and Exhibit Batch Production

- Activities: Scaling up production, producing exhibit batches for regulatory submission.
- Timeline: 9-12 months.
- Budget: \$500,000 - \$1,000,000.
- Risks: Scale-up issues, batch production failure.
- Mitigation: Detailed scale-up plans, rigorous quality control.

2.7 Pivotal Studies

- Activities: Extensive clinical trials, gathering pivotal data.
- Timeline: 12-18 months.
- Budget: \$1,000,000 - \$2,000,000.
- Risks: Clinical trial failures, adverse patient reactions.
- Mitigation: Thorough trial design, extensive patient monitoring.

2.8 Stability Data Collection

- Activities: Long-term and accelerated stability studies.
- Timeline: 12-24 months.
- Budget: \$200,000 - \$400,000.
- Risks: Product instability, data inconsistency.
- Mitigation: Comprehensive stability protocols, consistent data review.

2.9 Regulatory Submissions (ANDA and EMA Filing)

- Activities: Preparing and submitting regulatory dossiers.
- Timeline: 6-12 months.
- Budget: \$300,000 - \$600,000.
- Risks: Regulatory rejection, incomplete dossiers.
- Mitigation: Detailed dossier preparation, thorough regulatory review.

3. Risk Analysis and Mitigation

3.1 Potential Risks

- Development delays.
- Budget overruns.
- Regulatory hurdles.

3.2 Mitigation Strategies

- Implementing robust project management tools.
- Establishing cross-functional teams.
- Regular risk assessment and management.

4. Tools and Techniques

4.1 Project Management Tools

- Gantt charts for timeline planning.
- Budget tracking software.
- Risk management frameworks.

4.2 Collaboration Techniques

- Regular cross-functional meetings.
- Use of collaborative platforms (e.g., Microsoft Teams, Slack).

4.3 Key Performance Indicators (KPIs)

- On-time completion of milestones.
- Adherence to budget.
- Regulatory approval rates.

5. Conclusion

This internship provided valuable insights into the strategic management of OSD generic drug development. By meticulously planning each phase, identifying and mitigating risks, and utilizing effective tools and techniques, successful drug development and regulatory approval can be achieved. The knowledge and experience gained through this project will be instrumental in future endeavors in the pharmaceutical industry.